Finally, it demonstrated that both the BDL mouse cognitive dysfunction phenotype and, critically, the underpinning cellular senescence, are limited by exposure to an FXR agonist (obeticholic acid, which is used as a second-line agent in the management of the archetypal human cholestatic liver disease PBC). Here, NR1H4 is linked to Cholestatic liver disease.